Liquidia Technologies, Inc. Common Stock, also called Liquidia Technologies, is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. Read More It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.